Durolane Manufacturer – About Galderma S.A.

Knee treatments like viscosupplementation, including Durolane, have become essential tools for managing osteoarthritis (OA) pain. According to the American Academy of Orthopaedic Surgeons, this approach can reduce pain and improve joint mobility for up to a year, providing significant relief to millions of patients annually.

Durolane, developed by Galderma S.A., is a leading option for knee OA pain relief. Its innovative single-injection therapy uses highly purified hyaluronic acid (NASHA technology) to mimic natural joint fluid, alleviating pain and inflammation while promoting smoother joint movement.

In this article, we will delve into Galderma S.A.’s history, its contributions to medical advancements like Durolane, and how its technologies have transformed pain management and joint health for osteoarthritis patients worldwide.

Key Takeaways

• Galderma S.A. is a global leader in dermatology and medical aesthetics. It has consistently advanced patient care through innovative solutions like Durolane, which utilizes NASHA technology for effective osteoarthritis management.
• Durolane’s single-injection therapy reduces knee pain and improves joint mobility with its highly purified hyaluronic acid formulation, ensuring long-lasting relief.
• Galderma’s commitment to rigorous research and development has established Durolane as a leading viscosupplement, setting high industry standards.
• With Bioventus now managing Durolane, its global accessibility and recognition continue to grow, ensuring broader patient benefits.

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices. Contact Doctor Medica today to order Durolane online for your practice.  

Introduction to Galderma S.A.

Galderma S.A. is a global leader in dermatology and medical aesthetics, committed to enhancing skin health and overall well-being. Founded in 1981, the company has a long history of developing innovative solutions across various areas, including dermatological treatments, cosmetic injectables, and therapeutic products.

Galderma’s mission is to provide advanced, science-driven solutions that improve patients’ quality of life. With a strong focus on safety, efficacy, and innovation, the company addresses diverse medical and aesthetic needs. Guided by values of integrity, customer focus, and excellence, Galderma continues to invest in research and development to stay at the forefront of dermatology and aesthetics.

History of Galderma S. A.

Galderma S.A. was established in 1981 as a joint venture between Nestlé and L’Oréal, with a vision to become a global leader in dermatology. Over the decades, Galderma has achieved significant milestones, including developing pioneering medical and aesthetic products. Its portfolio includes acne, rosacea, psoriasis treatments, and innovative dermal fillers.

A key milestone in Galderma’s history was the development of Durolane, a single-injection hyaluronic acid treatment for osteoarthritis pain. Leveraging its patented NASHA technology, Durolane has become a leading option in viscosupplementation. In recent years, Bioventus acquired the rights to Durolane, allowing for expanded distribution and enhanced access for patients worldwide.

The comparison of Durolane vs Orthovisc highlights Durolane’s single-injection convenience against Orthovisc’s multi-injection protocol, further demonstrating Galderma’s commitment to creating patient-centered solutions. Through ongoing innovation and strategic collaborations, Galderma continues to set benchmarks in medical aesthetics and osteoarthritis management.

Commitment to Quality and Patient Outcomes

Galderma S.A. strongly emphasizes delivering high-quality products that prioritize patient safety and satisfaction. Every solution is backed by rigorous research and clinical testing to ensure effectiveness and minimize risks. This dedication to quality is evident in its development of innovative treatments like Durolane, which uses NASHA technology for enhanced joint lubrication and pain relief in osteoarthritis patients.

Galderma also focuses on creating patient-centered solutions that improve quality of life. By listening to feedback from both patients and healthcare professionals, the company tailors its innovations to address real-world needs. This commitment extends beyond product development, as Galderma actively supports healthcare providers with the tools and training to deliver the best possible patient outcomes.

Reputation in the Medical Aesthetics Field

Galderma S.A. has earned a stellar reputation as a global leader in medical aesthetics, known for its science-driven approach and dedication to safety and innovation. Its portfolio includes world-renowned products such as Restylane dermal fillers and Dysport, a botulinum toxin widely used for wrinkle reduction and facial rejuvenation.

By leveraging advanced research and clinical expertise, Galderma consistently delivers high-quality solutions that meet the needs of aesthetic professionals and patients. The company’s focus on providing natural-looking, long-lasting results has made it a trusted name among practitioners and individuals seeking non-surgical aesthetic enhancements. 

Research and Development Efforts

Before Bioventus acquired Durolane, Galderma developed the treatment using its patented NASHA (Non-Animal Stabilized Hyaluronic Acid) technology. This advanced formulation mimicked the natural properties of joint fluid, providing long-lasting pain relief with just a single injection.

The company’s R&D efforts focused on optimizing Durolane’s safety, efficacy, and convenience, addressing the needs of osteoarthritis patients who sought alternatives to multi-injection treatments. Through clinical trials and rigorous testing, Galderma established Durolane as a leading viscosupplement, enhancing patient mobility and quality of life. These efforts laid the foundation for the product’s global success and ensured its transition into the Bioventus portfolio.

Conclusion

Galderma S.A. has become a pioneer in dermatology and osteoarthritis treatments. Through innovative research and product development, the company introduced Durolane, a groundbreaking viscosupplement that has improved the lives of countless OA patients.

With its focus on patient outcomes and commitment to advancing medical science, Galderma has solidified its position as a trusted name in healthcare. With Durolane now part of the Bioventus portfolio, its accessibility and impact on joint health are expected to expand further.

FAQs

1. What is Durolane used for?

Durolane is a viscosupplement injection designed to treat knee osteoarthritis pain. It mimics the natural joint fluid to improve lubrication and cushioning.

2. Who manufactures Durolane?

Galderma S.A., a leader in dermatology and medical aesthetics, developed Durolane. It is now managed and distributed by Bioventus.

3. How long does Durolane provide relief?

Patients typically experience pain relief for up to six months after a single injection, although individual results may vary.

4. How does Durolane differ from other viscosupplements?

Unlike multi-injection treatments, Durolane uses a single-injection protocol, offering long-lasting pain relief through NASHA technology, a highly purified form of hyaluronic acid.

References

Tapasvi S, Mohanty SS, Acharya KKV, Bhattacharya K, Easwaran R, Charugulla SN. Viscosupplementation for Management of Knee Osteoarthritis from an Indian Perspective: An Expert Consensus Report. Pain and Therapy. 2019;8(2):217-231. doi:10.1007/s40122-019-0131-3

Leighton R, Fitzpatrick J, Smith H, Crandall D, Flannery CR, Conrozier T. Systematic clinical evidence review of NASHA (Durolane hyaluronic acid) for the treatment of knee osteoarthritis. Open Access Rheumatology Research and Reviews. 2018;Volume 10:43-54. doi:10.2147/oarrr.s162127

Drugs.com. (2023, August 14). Durolane injection: Uses, side effects & warnings. Retrieved November 18, 2024, from https://www.drugs.com/mtm/Durolane-injection.html